Waltham, MA-based Thermo Fisher Scientific is moving to expand its manufacturing footprint in Europe and North America with the addition of 15 new development and cGMP production lines at four of its facilities.
“We have continued to invest strategically in capacity, technology and expertise across our global network so we can accelerate innovation and enhance productivity for our customers,” Mike Shafer, senior vice president and president, pharma service for Thermo Fisher Scientific, said in a recent release. “This has enabled us to respond quickly and support our customers with unprecedented scale and depth of capabilities to meet high demand for new therapies and vaccines. By simplifying the supply chain and solving complex manufacturing challenges, we shorten development timelines in order to get high-quality medicines to patients faster.”
The company will expand its plants in Greenville, NC, Swindon, UK, and Ferentino and Monza in Italy. New assets will support the development of sterile drug products and the production of medicines, therapies, and vaccines.
Thermo Fisher Scientific also recently announced expansions in Asia, including a new sterile manufacturing plant in Singapore and a new integrated biologics and sterile drug development and manufacturing site in Hangzhou, China.
“With these investments, we’ve nearly doubled our global footprint for drug development and commercial manufacturing, which allows us to support our customers with unmatched flexibility, expertise and scale at a time of unprecedented demand,” Shafer said.